Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

被引：1
|
作者：
Muresan, Bogdan [1 ]
Mamolo, Carla [2 ]
Cappelleri, Joseph C. [2 ]
Shapiro, Mark [2 ]
Crescenzo, Rocco J. [2 ]
Su, Yun [2 ]
Heeg, Bart [1 ]
机构：
[1] Ingress Hlth, Rotterdam, Netherlands
[2] Pfizer Inc, New York, NY USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3095.3095
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3095
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
    Cortes, Jorge E.
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Crescenzo, Rocco J.
    Su, Yun
    Gambacorti-Passerini, Carlo
    Heeg, Bart
    Smith, B. Douglas
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1615 - 1622
  • [2] A MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS PONATINIB, NILOTINIB AND DASATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS AFTER ≥2 TYROSINE KINASE INHIBITORS
    Atallah, E. L.
    Maheshwari, V
    Mauro, M. J.
    Boquimpani, C.
    Rea, D.
    Hochhaus, A.
    Minami, Y.
    Saini, L.
    Corbin, R.
    VALUE IN HEALTH, 2022, 25 (07) : S521 - S521
  • [3] An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Leip, Eric
    Viqueira, Andrea
    Heeg, Bart
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 801 - 809
  • [4] Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
    Signorovitch, James E.
    Wu, Eric Q.
    Betts, Keith A.
    Parikh, Kejal
    Kantor, Evan
    Guo, Amy
    Bollu, Vamsi K.
    Williams, Denise
    Wei, L. J.
    DeAngelo, Daniel J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (06) : 1263 - 1271
  • [5] Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison
    Levy, Moshe Yair
    McGarry, Lisa J.
    Huang, Hui
    Lustgarten, Stephanie
    Chiroli, Silvia
    Iannazzo, Sergio
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (03) : 479 - 487
  • [6] MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) ANALYSIS FOR PONATINIB VS BOSUTINIB IN THIRD-LINE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Iannazzo, S.
    McGarry, L.
    Lustgarten, S.
    Chiroli, S.
    VALUE IN HEALTH, 2016, 19 (07) : A577 - A577
  • [7] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
    Khoury, H. Jean
    Kim, Dong-Wook
    Zaritskey, Andrey
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Navarro, Juan
    Rapoport, Aaron P.
    Dorlhiac-Llacer, Pedro Enrique
    Zanichelli, Maria
    Kelly, Virginia
    Besson, Nadine
    McMullan, Trevor
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 391 - 391
  • [8] One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison
    Signorovitch, James E.
    Betts, Keith A.
    Reichmann, William M.
    Thomason, Darren
    Galebach, Phil
    Wu, Eric Q.
    Chen, Lei
    DeAngelo, Daniel J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (02) : 315 - 322
  • [9] Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
    Garcia-Gutierrez, Valentin
    Huang, Fei
    Ashaye, Ajibade
    Dalal, Mehul
    Laliman-Khara, Victor
    Breccia, Massimo
    Rutherford, Megan
    Moradian, Hoora
    Patos, Petros
    Jabbour, Elias Joseph
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
12345